Safinamide + Safinamide + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Parkinson's Disease
Conditions
Parkinson's Disease
Trial Timeline
Jun 1, 2005 → Jul 1, 2007
NCT ID
NCT00642889About Safinamide + Safinamide + Placebo
Safinamide + Safinamide + Placebo is a phase 3 stage product being developed by Newron Pharmaceuticals for Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00642889. Target conditions include Parkinson's Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01286935 | Phase 3 | Completed |
| NCT01187966 | Phase 3 | Completed |
| NCT00642889 | Phase 3 | Completed |
| NCT00643045 | Phase 3 | Completed |
Competing Products
20 competing products in Parkinson's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| UB-312 + Placebo | Vaxxinity | Phase 1 | 25 |
| NAV5001 + DaTscan | Navidea Biopharmaceuticals | Phase 3 | 69 |
| piclozotan + 0.9% sodium chloride (normal saline) | Daiichi Sankyo | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Phase 3 | 77 |
| GPI 1485 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 3 | 77 |
| Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo | Eisai | Phase 3 | 77 |
| perampanel + placebo | Eisai | Phase 2 | 52 |
| Lemborexant + placebo | Eisai | Approved | 85 |
| Placebo + E2007 + E2007 | Eisai | Phase 3 | 77 |
| E2007 + E2007 + E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| 2 mg perampanel + 4 mg perampanel + placebo comparator | Eisai | Phase 3 | 77 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 2 | 52 |
| Istradefylline 20 mg or 40 mg | Kyowa Kirin | Phase 3 | 77 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 3 | 77 |
Other Products from Newron Pharmaceuticals
Safinamide (as add-on therapy) + Safinamide (as add-on therapy) + Safinamide (as add-on therapy)Phase 3
69
Safinamide + Safinamide + PlaceboPhase 3
69
Safinamide + Safinamide + PlaceboPhase 3
69
Evenamide 15 mg bid + PlaceboPhase 3
69
Safinamide, MAO-B inhibitor + Safinamide, MAO-B inhibitor + PlaceboPhase 3
69